OTC dental products
Executive Summary
Representatives for Vipont (Viadent), Pfizer (Plax) and Warner-Lambert (Listerine) met with FDA Chief Counsel Margaret Porter and other agency officials on April 20 to discuss whether "products intended for the treatment of plaque and similar conditions" are drugs or cosmetics, according to a memorandum of the meeting. The three companies have received reg and/or warning letters from FDA concerning plaque/gingivitis claims deemed by the agency to be drug claims. Drug Labeling Compliance Div. Director Richard Chastonay told a recent FDLI-sponsored meeting that FDA and industry may have reached an "impasse" on the OTC dental claims issue and that the agency may initiate legal actions.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.